These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32965001)

  • 1. Duchenne muscular dystrophy: preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction.
    Lamendola P; Lanza GA; Melita V; Villano A; Palermo C; Leone D; Lombardo A; Pennestrì F; Crea F; Mercuri EM; Pane M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9112-9115. PubMed ID: 32965001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of one-month sacubitril/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy.
    Papa AA; Gallinoro E; Palladino A; Golino P
    Acta Myol; 2020 Sep; 39(3):136-140. PubMed ID: 33305170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
    Briasoulis A; Kuno T; Ueyama H
    Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504
    [No Abstract]   [Full Text] [Related]  

  • 5. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
    J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy.
    Kim HM; Kim KH; Park JS; Oh BH
    Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33922990
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.
    Wang H; Fu X
    Coron Artery Dis; 2021 Aug; 32(5):418-426. PubMed ID: 32732515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction.
    Khan Z; Gholkar G; Tolia S; Kado H; Zughaib M
    Int J Cardiol; 2018 Nov; 271():169-173. PubMed ID: 30093137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Eur J Heart Fail; 2020 Nov; 22(11):2018-2025. PubMed ID: 32946164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
    Polito MV; Silverio A; Rispoli A; Vitulano G; Auria F; De Angelis E; Loria F; Gigantino A; Bonadies D; Citro R; Carrizzo A; Galasso G; Iaccarino G; Vecchione C; Ciccarelli M
    Sci Rep; 2020 Apr; 10(1):6665. PubMed ID: 32313194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sacubitril/valsartan in patients with left ventricular assist devices: Case series.
    Zorz N; Frljak S; Vrtovec B
    Artif Organs; 2021 Feb; 45(2):185-186. PubMed ID: 32885450
    [No Abstract]   [Full Text] [Related]  

  • 20. Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder.
    Monzo L; Lanzillo C; Tota C; Lino S; Fusco A; Minati M; Martino A; Calò L
    Curr Med Res Opin; 2019 May; 35(sup3):3-6. PubMed ID: 30894032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.